New insights into the biology and treatment of minimal change disease and focal segmental glomerulosclerosis

Our understanding of immune-mediated podocytopathy is rapidly evolving, and changes in treatment paradigms are likely to continue to change, with emphasis on targeted therapies addressing disease pathogenesis. Future prospective studies are required to understand the optimal use of antinephrin antibodies for diagnosis and monitoring and how to tailor therapy to individual patients.